Texcell — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Texcell is a global leader in specialized biosafety services, providing critical viral safety, viral clearance, and bioassay testing to support the development of biologics and advanced therapies. With deep roots dating back to a founding within the Pasteur Institute in 1987, the company leverages decades of scientific expertise to help clients mitigate contamination risks and meet regulatory requirements. Its global footprint and focus on high-growth sectors like cell and gene therapy position it as a key enabler for bringing safe therapeutics to market.

Cell TherapyBiologicsInfectious Disease

Technology Platform

Specialized biosafety services platform encompassing Cell Banking, Viral Safety Testing, Viral Clearance Studies, and in vitro/in vivo Bioassays for biopharmaceuticals and advanced therapies.

Opportunities

The explosive growth of cell and gene therapies and the sustained expansion of the biologics market create a large, non-discretionary demand for viral safety services.

Geographic expansion into key biopharma hubs like China presents a significant opportunity to capture market share in high-growth regions.

Risk Factors

Revenue is dependent on client R&D spending, which can be cyclical.

The company faces regulatory risk, as changes in guidelines or compliance failures could impact its operations, and competitive pressure from both specialized firms and larger CROs.

Competitive Landscape

Texcell competes in the specialized biosafety CRO segment against other niche players and the biosafety divisions of large, full-service CROs (e.g., Labcorp, Charles River). Its differentiation lies in its deep virology heritage, focus on high-complexity therapies, and integrated global service network.

More companies in Cell & Gene Therapy →More companies in France →